tbuckley/cabot-search huggingface dataset:
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
Authors: Charles S. Fuchs, Andrew E. Denker, Josep Tabernero, Eric Van Cutsem, Atsushi Ohtsu, Baohoang Lam, Minori Koshiji, Yung-Jue Bang
Journal: Journal of Clinical Oncology (2016)

TPS184 Background: Pembrolizumab (pembro) is a humanized monoclonal antibody that targets the PD-1 receptor and prevents it from interacting with its ligands, PD-L1 and PD-L2. In the phase I KEYNOTE-012 trial, pembro showed an acceptable safety profile and promising antitumor activity in patients (pts) with PD-L1 + metastatic gastric cancer. The multicohort, phase II KEYNOTE-059 (NCT02335411) trial was designed to further evaluate pembro as monotherapy or in combination with 5-fluorouracil (5-FU) and cisplatin in pts with advanced gastric cancer. Methods: Patients ≥ 18 y who have relapsed or metastatic gastric or GEJ adenocarcinoma, ECOG PS 0-1, no active autoimmune disease or brain metastases, and no prior chemotherapy within 2 wk of the first dose of pembro are eligible. PD-L1 expression status will be determined by IHC using the 22C3 antibody (Merck). In cohort 1 (C1), up to 180 pts with any PD-L1 status whose disease progressed on ≥ 2 prior chemotherapy regimens, including a fluoropyrimidine and platinum doublet and, if HER2 + , trastuzumab, will receive pembro 200 mg Q3W. In cohort 2 (C2), ~12 Asian and ~6 non-Asian, treatment-naive, HER2 – pts of any PD-L1 status will receive pembro 200 mg Q3W + infusional 5-FU or capecitabine and 6 cycles of cisplatin. In cohort 3 (C3), ~25 treatment-naive pts with HER2 – /PD-L1 + tumors will receive pembro 200 mg Q3W. Treatment may continue for up to 24 mo or until progression, intolerable toxicity, or investigator decision. Response will be assessed at wk 9 and every 6 wk thereafter per RECIST v1.1 and RECIST v1.1 adapted for immunotherapy response patterns. Treatment may be discontinued for eligible pts who have a CR. Eligible pts may continue treatment beyond initial RECIST-defined progression. AEs will be collected throughout the study and for 30 d thereafter (90 d for serious AEs) and graded per NCI CTCAE v4.0. The primary efficacy end point for C1 and C3 is ORR per RECIST v1.1 by central review; the primary end point for C2 is safety and tolerability of the combination. Secondary end points include PFS, OS, DCR, and duration of response. Enrollment in KEYNOTE-059 is ongoing and will continue until up to 223 pts are enrolled across all cohorts. Clinical trial information: NCT02335411.
Response of Hematopoietic Cell Lines Derived From Patients With Down's Syndrome and From Normal Individuals to Mitomycin C and Caffeine 2
Authors: A. Banerjee, O. Jung, C. C. Huang
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Response of Hematopoietic Cell Lines Derived From Patients With Down's Syndrome and From Normal Individuals to Mitomycin C and Caffeine Get access A. Banerjee, A. Banerjee Search for other works by this author on: Oxford Academic PubMed Google Scholar O. Jung, O. Jung Search for other works by this author on: Oxford Academic PubMed Google Scholar C. C. Huang C. C. Huang 6 6Address requests for reprints to Dr. C. C. Huang. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 1, July 1977, Pages 37–39, https://doi.org/10.1093/jnci/59.1.37 Published: 01 July 1977 Article history Received: 09 September 1976 Accepted: 16 February 1977 Published: 01 July 1977
Familial Hepatitis
Authors: T V Nowak
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Azacitidine Improves Survival in Myelodysplastic Syndromes; Single Institute Retrospective Study
Authors: June Takeda, Nobuhiko Yamauchi, Kazunari Aoki, Yuichiro Ono, Yuki Funayama, Yasuhiro Kazuma, Yosuke Nagahata, Yotaro Ochi, Yusuke Koba, Sumie Tabata, Nobuhiro Hiramoto, Akiko Matsushita, Noboru Yonetani, Hisako Hashimoto, Takayuki Ishikawa
Journal: Blood (2013)
Immunophenotypic Profile of Acute Leukemia: Critical Analysis and Insights Gained at a Tertiary Care Center in India
Authors: Sumeet Gujral, Y. Badrinath, Ashok Kumar, Pg Subramanian, G Raje, H Jain, A Pais, Ps amre Kadam, Sd Banavali, B. Arora, P Kumar, Vg hari Menon, Pa Kurkure, Pm Parikh, S Mahadik, Ab Chogule, Sc Shinde, Cn Nair
Journal: Blood (2008)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Authors: Benjamin L. Lampson, Siddha N. Kasar, Tiago R. Matos, Elizabeth A. Morgan, Laura Rassenti, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Caron A. Jacobson, Philippe Armand, Jeremy S. Abramson, Jon E. Arnason, Thomas J. Kipps, Joshua Fein, Stacey Fernandes, John Hanna, Jerome Ritz, Haesook T. Kim, Jennifer R. Brown
Journal: Blood (2016)
Monoethylhexyl Phthalate Elicits an Inflammatory Response in Adipocytes Characterized by Alterations in Lipid and Cytokine Pathways
Authors: Sara Manteiga, Kyongbum Lee
Journal: Environmental Health Perspectives (2016)

A growing body of evidence links endocrine-disrupting chemicals (EDCs) with obesity-related metabolic diseases. While it has been shown that EDCs can predispose individuals toward adiposity by affecting developmental processes, little is known about the chemicals' effects on adult adipose tissue.Our aim was to study the effects of low, physiologically relevant doses of EDCs on differentiated murine adipocytes.We combined metabolomics, proteomics, and gene expression analysis to characterize the effects of mono-ethylhexyl phthalate (MEHP) in differentiated adipocytes.Repeated exposure to MEHP over several days led to changes in metabolite and enzyme levels indicating elevated lipogenesis and lipid oxidation. The chemical exposure also increased expression of major inflammatory cytokines, including chemotactic factors. Proteomic and gene expression analysis revealed significant alterations in pathways regulated by peroxisome proliferator activated receptor-γ (PPARγ). Inhibiting the nuclear receptor's activity using a chemical antagonist abrogated not only the alterations in PPARγ-regulated metabolic pathways, but also the increases in cytokine expression.Our results show that MEHP can induce a pro-inflammatory state in differentiated adipocytes. This effect is at least partially mediated PPARγ.
Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study
Authors: Ulrich Jaeger, Marek Trneny, Helen Melzer, Michael Praxmarer, Michael A. Fridrik, Weerasak Nawarawong, Dina Ben Yehuda, Biljana Mihaljevic, Osman Ilhan, Veronika Ballova, Michael Hedenus, Liang-Tsai Hsiao, Wing-Yan Au, Josef Thaler, Gerhard Weidinger, Felix Keil, Christian Dittrich, Cathrin Skrabs, Daniela Wolkersdorfer, Anton Klingler, Richard Greil, David Goldstein
Journal: Blood (2013)
The reporting of clinical trials: counting is not easy.
Authors: M Zelen
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.7.827 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2738621 The reporting of clinical trials: counting is not easy. M ZelenxM ZelenSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.7.827 PDF "The reporting of clinical trials: counting is not easy.." Journal of Clinical Oncology, 7(7), pp. 827–828© 1989 by American Society of Clinical Oncology
PD5-2-4: Phase I/II results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC
Authors: Jeffrey D. Bradley, Mary V. Graham, Jennifer Moughan, Roger Byhardt, Ramaswamy Govindan, Jack Fowler, James Purdy, Jeff M. Michalski, Elizabeth Gore, Hak Choy
Journal: Journal of Thoracic Oncology (2007)
Ponds
Authors: Lewis Thomas
Journal: New England Journal of Medicine (1978)

LARGE areas of Manhattan are afloat. I remember when the new Bellevue was being built, 15 years ago; the first stage was the most spectacular and satisfying, an enormous square lake. It was there for two years, named Lake Bellevue, while the disconsolate Budget Bureau went looking for cash to build the next stage. It was fenced about and only visible from the upper windows of the old hospital, but pretty to look at, cool and blue in midsummer, frozen gleaming as Vermont in January. The fence, like all city fences, was always broken, and we could have gone down . . .
A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
Authors: Tetsuo Tani, Kenzo Soejima, Katsuhiko Naoki, Daisuke Arai, Kouta Ishioka, Keiko Ohgino, Makoto Nishino, Aoi Kuroda, Hiroyuki Yasuda, Tomoko Betsuyaku
Journal: Journal of Clinical Oncology (2015)

e19039 Background: No consensus has been reached regarding the treatment order and timing of EGFR-TKI and cytotoxic chemotherapy for EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. Objective: To assess the efficacy and safety of induction Erlotinib (E) followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous NSCLC. Methods: In this phase II trial, 20 chemotherapy-naïve patients harboring activating EGFR mutations with stage IIIB/IV or recurrent non-squamous NSCLC and ECOG-PS 0-2 were enrolled. Patients were treated with induction E for 3 months followed by cytotoxic chemotherapy with Platinum + Pemetrexed +/- Bevacizumab, when the induction E achieved CR or PR. The primary endpoint was 1-year progression free survival (PFS) rate, while the secondary endpoints were response rate (RR), PFS, safety and overall survival. The minimum number of patients to be enrolled was 19 with an α error of 0.05 (one-sided) and a β error of 0.2. The threshold 1-year PFS rate was 35% and estimated 1-year PFS rate was 65%. Results: Twenty patients were enrolled in this study. The median age was 63 years. Eighteen patients had Stage IV disease, and 2 patients had recurrent disease. Eleven patients achieved PR after induction E and 9 patients were shifted to chemotherapy. One-year PFS rate was 52.8 (32.9-72.7)%, RR was 57.9%, and PFS was 12.7 (7.5-18.0) months in the ITT population. Grade 3-4 adverse events were reported for 40% of the patients, including leukopenia (10%), neutropenia (20%), and interstitial pneumonitis, bacterial pneumonia, rash, and nausea (5% each). Conclusions: The primary endpoint of this study was not achieved. However, this therapy was well tolerated and may be a treatment option for future study with responded patients after short-term EGFR-TKI exposure. Clinical trial information: UMIN000013125.
Healthcare associated infections in university hospitals in Latvia, Lithuania and Sweden: a simple protocol for quality assessment
Authors: J Struwe, U Dumpis, J Gulbinovic, Å Lagergren, U Bergman
Journal: Eurosurveillance (2006)

Surveillance of healthcare associated infections is an overlooked parameter of good clinical practice in most healthcare institutions, due to the workload demanded in the absence of adequate IT-systems. The aim of the present study was to investigate whether a simple protocol could be used to estimate the burden of healthcare associated infections in three university hospitals in Huddinge in Sweden, Riga in Latvia and Vilnius in Lithuania and form the basis for initiating a long term follow up system. The medical records of all patients receiving antibiotics were reviewed according to a standardised protocol, focusing on the indications for the drugs and on the frequency of hospital acquired infection (HAI) in a point-prevalence survey. Only comparable specialities were included. The proportion of patients treated with antibiotics (prophylaxis not included) were 63/280 (22%) in Huddinge, 73/649 (11%) in Riga and 99/682 (15%) in Vilnius. The proportion of admitted patients treated for a HAI were 15%, 3% and 4%, respectively, (both comparisons Huddinge versus other centres P&amp;lt;0.001). Surgical site infections were most common, followed by infections with an onset more than 2 days after admission without any of the other registered risk factors present. Our inexpensive and simple method showed that healthcare associated infections were a significant problem among patients admitted to Huddinge. The figures obtained can be used for further discussion and form a baseline for follow up at the local level. The comparison of figures between centres was far less relevant than the process the study created.
The rapid quality reporting system: Assessing and improving the quality of cancer care with a prospective clinical performance tracking and reporting system.
Authors: Erica J. McNamara, Andrew Stewart, E. Greer Gay, James Banasiak, Bryan E. Palis, Stephen B. Edge
Journal: Journal of Clinical Oncology (2012)

286 Background: The Rapid Quality Reporting System (RQRS), developed by The Commission on Cancer of The American College of Surgeons, allows accredited cancer programs to prospectively monitor adherence to five National Quality Forum endorsed quality of care metrics for breast (BC) and colon (CC) cancer. This study assesses differences in performance rates by patient populations and demonstrates the impact a prospective clinical performance tracking system can have in impacting care. Methods: RQRS tracks and measures compliance with the following measures: Radiation therapy within one year of diagnosis (dx) for women &lt;70 receiving breast conserving surgery for BC (BCS/RT); hormone therapy within one year of dx for AJCC T1c, N0M0, or stage II or II; hormone receptor positive BC (HT); multi-agent chemotherapy within four months of dx; age &lt; 70; hormone receptor negative BC (MAC); adjuvant chemotherapy within four months of dx; age &lt;80; AJCC stage III CC (ACT); pathologic examination of ≥12 regional lymph nodes for surgically resected CC (12RLN). 64,129 RQRS measure eligible cases diagnosed from 2006 to 2010 from 64 RQRS beta test centers were assessed. Performances rates, before and after implementing the RQRS beta test, were compared by patient demographics. Results: Between 2006 to 2010, compliance rates increased significantly for all five measures, ranging from a 16% increase for MAC to 36% for HT. Prior to RQRS participation, BCS/RT, HT and ACT compliance was significantly lower in patients of other races cf. to white and black; for MAC, other races were lower cf. to white. By 2010 a difference by race remained only in BCS/RT. Payer status and age also impact care. Private insurance cases were more likely to receive compliant care for BCS/RT, MAC and 12RLN; with Medicare for HT (p&lt;.05). Age impacted HT (&lt;40 less likely) and ACT (70-79 less likely cf. to 40-49) (p&lt;.05). Conclusions: Increased performance rates show a system which promotes the ability to track patients in real clinical time can improve quality of care. By using RQRS to prospectively monitor expected adjuvant care, programs can proactively intervene and address potential issues that could impede delivery of timely standard of care.
FDG PET/CT Findings of Intracardiac Myeloid Sarcoma
Authors: Na Niu, Ruixue Cui, Fang Li
Journal: Clinical Nuclear Medicine (2015)

Myeloid sarcoma is a rare entity, and cardiac involvement is even rarer. We presented here the FDG PET/CT findings of a 66-year-old man with a 3-month history of cough and progressive dyspnea. FDG PET/CT scan demonstrated nonuniform FDG uptake in the cardiac walls and pericardium. Biopsy of the heart revealed myeloid sarcoma. In addition, bone marrow biopsy demonstrated the acute myeloid leukemia.
Prospectively measuring the acuity of outpatient chemotherapy treatment regimens for staffing allocation.
Authors: Shani Michelle Weber, Cheryl A. Steele
Journal: Journal of Clinical Oncology (2016)

48 Background: UPMC CancerCenter is a large outpatient medical oncology network of 25 locations, located within a 200 mile radius of Pittsburgh, PA. Covering all of these centers with a limited pool of float nurses was a daily challenge. The literature describes many attempts to quantify nursing workload retrospectively based upon complexity, hours of nursing time, etc. The ability to schedule staff equitability in advance is critical to managing staff. New targeted therapies and complicated treatment regimens which impact patient acuity bring to light the need for accurate acuity measurement. Methods: The first step in designing an acuity model was to determine the level of complexity of each treatment regimen based on standardized criteria. The model is a five point system encompassing route, teaching, reaction potential, etc. designed by frontline nurses. A designated nurse at each site calculates the acuity and enters it into an online system prospectively. Nursing Administration can view the staffing and acuity rating across the entire network. This enables the assignment of float nurses to the location with the greatest need. Results: A stoplight report using the database was developed to highlight the sites that are outside of 0.5 standard deviation (SD) range for both the acuity and patient ratios. It was determined that the average nurse to acuity ratio was 11.92 (within SD range 10.69-13.16). The average nurse to patient ratio was 6.31 (within SD range 5.6-7.03). This enables Nursing Administration to identify sites that typically operate below or above the average range in order to better allocate nursing resources. This report is shared among all sites to provide transparency which has improved understanding by the staff of nursing resource allocation. Conclusions: The development of this prospective acuity system has helped to quantify treatment complexity to better allocate daily staffing resources. Further evaluation is necessary to determine the optimal ratios that are the most economical while still providing safe patient care. There are future plans to link the acuity levels to treatment regimens within the Electronic Medical Record to reduce the manual workload.
JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.
Authors: Herbert Hurwitz, William M. Garrett, Jason Clark, Kimberli J. Brill, Fitzroy W. Dawkins, Manuel Hidalgo, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2015)

TPS4147 Background: The systemic inflammatory response observed in PC is a negative prognostic factor and is mediated in part by JAK-STAT signaling. Treatment with the JAK1/JAK2 inhibitor ruxolitinib in combination with capecitabine was previously investigated as second-line therapy for patients with mPC and evidence of a systemic inflammatory response (elevated C-reactive protein [CRP] levels or a modified Glasgow Prognostic Score [mGPS] of 1 or 2) in the phase 2, randomized, double-blind RECAP study. Results showed improved overall survival (OS) relative to placebo + capecitabine (Hurwitz et al. J Clin Oncol. 32:5s, 2014 [suppl; abstr 4000]). Ruxolitinib has US Food and Drug Administration orphan drug status for the treatment of PC. Methods: JANUS 1 is a phase 3, international, multicenter, randomized, double-blind study. Eligible patients are ≥ 18 years of age with histologically or cytologically confirmed pancreatic adenocarcinoma that is advanced and inoperable or metastatic; have an ECOG performance status of 0–2; have received 1 prior chemotherapy regimen for advanced or metastatic PC not including neoadjuvant and/or adjuvant therapy; and have an mGPS of 1 (CRP > 10 mg/L and albumin ≥ 35 g/L) or 2 (CRP > 10 mg/L and albumin < 35 g/L). Patients are excluded for > 1 prior chemotherapy regimen for advanced or metastatic disease; radiation therapy; concurrent anticancer therapy; or prior severe reaction to fluoropyrimidines, dihydropyrimidine dehydrogenase deficiency, or other sensitivity to 5-fluorouracil. Patients are randomized 1:1 to receive 21-day cycles of capecitabine 2000 mg/m2/d (days 1–14) + ruxolitinib 15 mg twice-daily or capecitabine 2000 mg/m2/d + placebo twice-daily. The primary endpoint is OS. Secondary endpoints include progression-free survival, tumor response per RECIST 1.1, and duration of response. Treatment will continue as long as it is tolerated and discontinuation criteria are not met. Patients who discontinue treatment will be followed for subsequent anticancer treatments and survival. Enrollment was initiated in March 2014 and is ongoing. The planned enrollment is 310 patients. Clinical trial information: NCT02117479.